Drugs / TAEST16001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03159585 | Apr 2017 → Jun 2019 | breast cancer, connective and soft tissue neoplasm, esophageal cancer, gastric cancer +5 | Zhujiang Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03029273 | Mar 2017 → Mar 2019 | non-small cell lung carcinoma | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05549921 | Jul 2022 → Jul 2025 | soft tissue sarcoma | Sun Yat-sen University | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAEST16001 | “This study will investigate the safety and tolerability of TAEST16001 (TAEST: TCR Affinity Enhancing Specific T cell Therapy, autologous T cells transduced with affinity...” NCT03029273 ↗ |
| Modality | Cell therapy | “TAEST16001 (TAEST: TCR Affinity Enhancing Specific T cell Therapy, autologous T cells transduced with affinity enhanced NY-ESO-1 TCR) cell therapy” NCT03029273 ↗ |
| Route | Intravenous | “will be intravenously (i.v.) administered” NCT03029273 ↗ |